CTRI/2022/10/046590尚未招募未知
Efficacy and safety of oral Tolvaptan versus intravenous Furosemide in childhood Nephrotic Syndrome with edema â?? an Open Labelled Randomised Controlled Trial
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Nephrotic syndrome aged between 5 and 14 years with moderate to severe edema
- •2) Patients not responding to oral furosemide for up to 24 hours (decrease in 3% body weight or urine output < 1 ml/kg/hour)
- •3) Parents willing to give informed written consent
排除标准
- •1) Patients with hypovolemia
- •2) Patients with cerebral venous sinus thrombosis
- •3) Serum sodium < 125 or > 140 meq/L
- •4) eGFR < 60 ml/min/1.73 m2
- •5) SGOT/SGPT > 2 ULN
研究者
相似试验
已完成
不适用
Comparison of Tolvaptan treatment and conventional treatment in elderly acute heart failure.Acute decompensated heart failureJPRN-UMIN000028039Iiyama redcross hospital60
已完成
不适用
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney DiseaseJPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
招募中
不适用
Efficasy and safety of tolvaptan in patients undergoing peritoneal dialysis with heart failure despite the standard treatment with conventionalJPRN-UMIN000008712Division of Kidney and Hypertension, the Jikei University School of Medicine40
已完成
4 期
Short term clinical efficacy and safety of Tolvaptan additional treatment compared with escalation treatment of conventional diuretics in HF patients with volume overload despite treatments with the conventional diureticscongestive heart failureJPRN-UMIN000009136Kyoto University Hospital40
已完成
不适用
Efficacy and safety of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failuresevere chronic kidney disease complicated by congestive heart failureJPRN-UMIN000029787Department of Nephrology, Nippon Medical School50